Solvonis Therapeutics Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	May '21 May 31, 2021
Revenue	-	-	0.59	0.54	0.52
Revenue Growth (YoY)	-	-	8.30%	4.23%	57.58%
Cost of Revenue	-	-	0.33	0.24	0.03
Gross Profit	-	-	0.26	0.3	0.49
Selling, General & Admin	3.02	1.15	2.15	2.67	0.65
Depreciation & Amortization Expenses	-	-	0.18	0.11	-
Other Operating Expenses	2.72	0.23	1.05	0.24	0.38
Total Operating Expenses	5.74	1.38	3.38	3.02	1.03
Operating Income	-3.48	-1.38	-3.12	-2.7	-0.44
Interest Expense	-	-0.06	-0	-0	-0.01
Total Non-Operating Income (Expense)	-	-0.06	-0	-0	-0.01
Pretax Income	-5.74	-1.45	-3.12	-2.71	-0.45
Net Income	-5.74	-1.45	-3.12	-2.71	-0.45
Earnings From Discontinued Operations	-	-0.14	-	-	-
Net Income to Common	-5.74	-1.59	-3.12	-2.71	-0.45
Shares Outstanding (Basic)	4,865	1,157	104	104	69
Shares Outstanding (Diluted)	4,865	1,157	104	104	69
Shares Change (YoY)	320.56%	1011.63%	0.45%	50.13%	1.47%
EPS (Basic)	-0.00	-0.00	-0.03	-0.03	-0.01
EPS (Diluted)	-0.00	-0.00	-0.03	-0.03	-0.01
Free Cash Flow	-3.27	-1.13	-1.45	-3.08	-0.18
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.03	-0.00
Gross Margin	-	-	43.95%	55.35%	94.23%
Operating Margin	-	-	-531.00%	-498.34%	-85.38%
Profit Margin	-	-	-531.52%	-499.08%	-86.73%
FCF Margin	-	-	-247.70%	-567.90%	-34.81%
EBITDA	-3.48	-1.38	-2.94	-2.59	-0.34
EBITDA Margin	-	-	-500.85%	-477.49%	-64.42%
EBIT	-3.48	-1.38	-3.12	-2.7	-0.44
EBIT Margin	-	-	-531.00%	-498.34%	-85.38%